Introduction: National transplant registries routinely focus on centre-specific patient and graft survival rates following renal transplantation. However other outcomes such as graft function (as measured by eGFR), haemoglobin and blood pressure are also important quality of care indicators. Methods: Renal transplant activity, incident graft survival data and donor information were obtained from NHS Blood and Transplant. Laboratory and clinical variables and prevalent survival data were obtained from the UK Renal Registry. Data were analysed separately for prevalent and one year post-transplant patients. Results: The main increase in transplant activity in 2013 was the use of donors after brainstem death. The death-censored graft failure rate was similar to previous years at 2.4% and the transplant patient death rates remained stable at 2.4 per 100 patient years. There was centre variation in outcomes including eGFR and haemoglobin in prevalent and 1 year posttransplant patients. Analysis of prevalent transplants by chronic kidney disease stage showed 13.4% with an eGFR ,30 ml/min/1.73 m 2 and 1.7% with an eGFR ,15 ml/min/ 1.73 m 2 . Of those with CKD stage 5T, 32.4% had haemoglobin concentrations ,100 g/L 28.4% phosphate concentrations 51.7 mmol/L and 16.8% adjusted calcium concentrations 52.5 mmol/L. Infection (26%) and malignancy (24%) remained amongst the commonest causes of death in patients with a functioning renal transplant. Conclusion: Significant variations in clinical outcomes (unadjusted for patient specific variables) amongst kidney transplant recipients continued to exist in the UK and may reflect differences in healthcare delivery between renal centres. 
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Introduction
This chapter includes independent analyses regarding renal transplant activity and survival data from the UK Transplant Registry, held by the Organ Donation and Transplantation Directorate (ODT) of NHS Blood and Transplant (NHSBT). The UK Renal Registry (UKRR) has performed additional analyses of renal transplant recipient follow-up data examining demographics, clinical and biochemical variables. NHSBT records all the information regarding the episode of transplantation (donor and recipient details) and the UKRR holds additional information on key clinical and biochemical variables in renal transplant recipients. The co-operation between these two organisations results in a comprehensive database describing the clinical care delivered to renal transplant patients within the UK. This further allows for the comparison of key outcomes between centres and provides insight into the processes involved in the care of such patients in the UK.
This chapter is divided into six sections: (1) transplant activity, waiting list and survival data; (2) transplant demographics; (3) clinical and laboratory outcomes; (4) analysis of prevalent patients by chronic kidney disease (CKD) stage; (5) eGFR slope analysis; and (6) cause of death in transplant recipients. Methodology, results and conclusions of these analyses are discussed in detail for all six sections separately.
The UK Renal Registry methodology is described elsewhere [1] . The UKRR collects quarterly clinical data via an electronic data extraction process from hospital based renal IT systems on all patients receiving renal replacement therapy. Throughout the chapter, the number preceding the centre name in each figure indicates the percentage of missing data for that centre for that variable.
Unless otherwise specified, prevalent transplant patients were defined as patients with a functioning renal transplant on the 31st December 2013.
NHSBT prospectively collects donor and recipient data around the episode of transplantation. They also request that transplant centres provide an annual paper based data return on the status of the recipient's graft function. This enables ODT to generate comprehensive analyses of renal transplant activity and graft survival statistics.
NHSBT attributes a patient to the centre that performed the transplant operation irrespective of where the patient was cared for before or after the procedure and hence only reports on transplant centre performance.
Methods
In 2013, there were 23 UK adult renal transplant centres, 19 in England, two in Scotland and one each in Northern Ireland and Wales.
Comprehensive information from 1999 onwards concerning the number of patients on the transplant waiting list, the number of transplants performed, the number of deceased kidney donors (donor after brainstem death and donor after circulatory death), living kidney donors, patient survival and graft survival is available on the NHSBT website (http://www.organdonation.nhs.uk/ukt/ statistics/statistics.asp).
Results
During 2013, 3,257 kidney or kidney plus other organ transplants were performed. The absolute number of living kidney donors showed a 6% rise in 2013 representing 33.8% of all transplants performed whilst donor after circulatory death transplants continued to increase and comprised 24.4% of all kidney transplants performed. A 20% rise in the number of transplants from donors after brainstem death was also noted in 2013 (table 3.1).
There were small differences in one and five year risk-adjusted patient and graft survival rates amongst UK renal transplant centres (table 3. 2). These graft survival rates include grafts with primary non-function (which are excluded from analysis by some countries).
Using data from the UKRR on prevalent renal transplant patients on 1st January 2013, the death rate during 2013 was 2.4/100 patient years (CI 2.2-2.6) when censored for return to dialysis and 2.5/100 patient years (CI 2.3-2.7) without censoring for dialysis. These death rates are similar to those observed over the last few years and have not shown any impact of the increasing age of the transplanted cohort.
During 2013, 2.4% of prevalent transplant patients experienced graft failure (excluding death as a cause of graft failure) maintaining the fall in graft failure rates noted over the last couple of years. Whilst it might be premature to assume that graft failure rates are falling in the UK the 0.5% fall noted in the last five years is certainly encouraging.
Conclusions
In 2013, the increased number of kidney transplants performed was mostly due to an increase in organs from donors after brainstem death. The graft failure The following sections need to be interpreted in the context of variable repatriation policies; some transplant centres continue to follow up and report on all patients they transplant, whereas others refer patients back to nontransplant centres for most or all ongoing post-transplant care. Some transplant centres only refer back patients when their graft is failing. The time post-transplantation that a patient is referred back to their local centre varies between transplant centres. The UKRR is able to detect duplicate patients (being reported from both transplant and referring centres) and in such situations care is usually attributed to the referring centre (see appendix B2 for allocation procedure). This process may result in some discrepancies in transplant numbers particularly in Oxford/Reading and Clywd/Liverpool Royal.
Methods
Two centres (Bangor and Colchester) did not have any transplant patients and were excluded from some of the analyses. Their dialysis patients were included in the relevant dialysis population denominators.
For the analysis of primary renal diagnosis (PRD) in transplant recipients, a few centres were excluded from some of the take-on years because of concerns relating to the reliability of PRD coding (with these centres submitting a high percentage of uncertain or missing aetiology codes).
Information on patient demographics (age, gender, ethnicity and PRD) for patients in a given renal centre was obtained from UKRR patient registration data fields. Individual patients were assigned to the centre that returned data for them during 2013. The prevalence of transplant patients in areas covered by individual Clinical Commissioning Groups (CCG) or Health Board/Social Care Areas (HB) was estimated based on the postcode of the registered address for patients on renal replacement therapy (RRT). Data on ethnic origin, supplied as Patient Administration System (PAS) codes, were retrieved from fields within renal centre IT systems. For the purpose of this analysis, patients were grouped into Whites, South Asians, Blacks, Others and Unknown. The details of ethnicity regrouping into the above categories are provided in appendix H: Coding http://www.renalreg.org.
Results and Conclusions
Prevalent transplant numbers across the UK are described in table 3.3.
The prevalence of renal transplant recipients in each CCG/HB in England, Northern Ireland (Health and Social Care Trust Areas), Scotland (Health Boards) and Wales (Local Health Boards) and the proportion of prevalent patients according to modality in the renal centres across the UK is described in tables 3.4 and 3.5 respectively. After standardisation for age and gender, unexplained variability was evident in the prevalence of renal transplant recipients, with some areas having higher than the predicted number of prevalent transplant patients per million population and others lower. There are a number of potential explanations for these inconsistencies, including geographical differences in access to renal transplantation in the UK. This has previously been analysed in detail by the UKRR [2] and is currently the focus of a large national study (access to Transplant and Transplant Outcome Measures (ATTOM)).
The proportion of prevalent RRT patients with a transplant relative to the number on dialysis has been relatively stable over the last decade.
Age and gender
The gender ratio amongst incident and prevalent transplant patients has remained stable for at least the last ten years (table 3.6, figure 3.1). Note, absolute patient numbers differ from those published in previous reports as a result of additional data validation and reallocation of patients. The average age of incident transplant patients has steadily increased during the same time period. There has also been a gradual increase in the average age of prevalent transplant patients, which could reflect the increasing age at which patients are transplanted and/or improved survival after renal transplantation over the last few years. The prevalent transplant patient workload across the UK increased to 29,592 patients at the end of 2013. The continued expansion of this patient group means there is a need for careful planning by renal centres for future service provision and resource allocation. 
Primary renal diagnosis
The primary renal diagnosis of patients receiving kidney transplants in the UK has remained relatively stable over the last five years (table 3.7).
Ethnicity
It was difficult to compare the proportion of patients within each ethnic group receiving a transplant to those commencing dialysis from the same group because data on ethnicity were missing in a considerable number of patients who were classified as ethnicity 'unknown' (table 3.8). The percentages of patients with unknown ethnicity between 2008 and 2013 provided in this year's chapter are different from those in last year's chapter [3] ; this reflects retrospective input of ethnicity data, improving data completeness.
Clinical and laboratory outcomes
Introduction There continued to be marked variation in the completeness of data (tables 3.9a, 3.9b) reported by each renal centre, particularly for blood pressure. Better data records (or possibly better extraction of data held within renal IT systems) would facilitate more meaningful comparisons between centres and help to determine the causes of inter-centre differences in outcomes. For this reason, along with differences in repatriation policies of prevalent transplant patients between centres as highlighted previously, caution needs to be exercised when comparing centre performance.
The 71 renal centres in the UK comprise 52 centres in England, five in Wales, five in Northern Ireland and nine in Scotland. Two centres (Bangor and Colchester) were reported as having no transplanted patients and were therefore excluded. After exclusion of these two centres, prevalent patient data from 69 renal centres across the UK were analysed.
For the one year post-transplant analyses, in which patients were assigned to the centre that performed their transplant, all 23 transplant centres across the UK were included in the analysis.
Methods
Data for key laboratory variables are reported for all prevalent patients with valid data returns for a given renal centre (both transplanting and non-transplanting centres) and for one year posttransplant results for patients transplanted 2006-2012, with patients attributed to the transplant centre that performed the procedure. Time since transplantation may have a significant effect on key biochemical and clinical variables and this is likely to be independent of a centre's clinical practices. Therefore, inter-centre comparison of data on prevalent transplant patients is open to bias. To minimise bias relating to fluctuations in biochemical and clinical parameters occurring in the initial post-transplant period, one year post-transplantation outcomes are also reported. It is presumed that patient selection policies and local clinical practices are more likely to be relevant in influencing outcomes 12 months post-transplant and therefore comparison of outcomes between centres is more robust. However, even the 12 months post-transplant comparisons could be biased by the fact that in some centres, repatriation of patients only occurs if the graft is failing whereas in others it only occurs if the graft function is stable.
Centres with ,20 patients or ,50% data completeness have been excluded from the figures. Scottish centres were also excluded from blood pressure analyses as data were not provided.
Prevalent patient data
Biochemical and clinical data for patients with a functioning transplant followed in either a transplanting or non-transplanting centre were included in the analyses. The cohort consisted of 832  92  77  90  90  74  M RI  1,188  98  65  98  98  64  Middlbr  449  88  50  86  85  10  Newc  621  99  87  99  99  62  Norwch  316  98  97  95  98  30  Nottm  592  98  84  96  93  88  Oxford  990  98  74  98  98  34  Plymth  310  92  56  88  87  39  Ports  825  95  57  93  88  24  Prestn  468  97  71  95  94  58  Redng  361  99  92  98  85  48  Salford  401  98  87  97  97  80  Sheff  660  99  65  98  98  26  Shrew  122  81  79  72  72  14  Stevng  248  96  81  92  80  57  Sthend  78  99  35  99  96  8  Stoke  318  99  100  99  98  69  Sund  212  98  96  98  97  95  Truro  199  97  61  97  97  34  Wirral  4  75  75  75  75  75  Wolve  177  96  86  93  83  64  York  240  94  64  89  86  20 prevalent patients as on 31st December 2013. Patients were considered as having a functioning transplant if 'transplant' was listed as the last mode of RRT in the last quarter of 2013. Patients were assigned to the renal centre that sent the data to the UKRR but some patients will have received care in more than one centre. If data for the same transplant patient were received from both the transplant centre and non-transplant centre, care was usually allocated to the non-transplant centre (see appendix B2). Patients with a functioning transplant of less than three months duration were excluded from analyses. For haemoglobin, estimated glomerular filtration rate (eGFR), corrected calcium, phosphate and blood pressure (BP), the latest value in quarter 3 or quarter 4 of 2013 was used.
Estimated glomerular filtration rate (eGFR)
For the purpose of eGFR calculation, the original 4-variable MDRD formula was used (with a constant of 186) to calculate eGFR from the serum creatinine concentration as reported by the centre (unless otherwise stated). A wide variety of creatinine assays are in use in clinical biochemistry laboratories in the UK, and it is not possible to ensure that all measurements of creatinine concentration collected by the UKRR are harmonised. Although many laboratories are now reporting assay results that have been aligned to the isotope dilution-mass spectrometry standard (which would necessitate use of the modified MDRD formula), this was not the case at the end of 2013. Patients with valid serum creatinine results but no ethnicity data were classed as White for the purpose of the eGFR calculation.
One year post-transplant data
Patients who received a renal transplant between 1st January 2006 and 31st December 2012 were assigned according to the renal centre in which they were transplanted. In a small number of instances, the first documented evidence of transplantation in a patient's record is from a timeline entry in data returned from a non-transplant centre, in these instances the patient was reassigned to the nearest transplant centre (table 3.10).
Patients who had died or experienced graft failure within 12 months of transplantation were excluded from the analyses. Patients with more than one transplant during 2006-2012 were included as separate episodes provided each of the transplants functioned for a year.
For each patient, the most recent laboratory or blood pressure result for the relevant 4th/5th quarter after renal transplantation was taken to be representative of the one year post-transplant outcome. Again, for the purpose of the eGFR calculation patients with valid serum creatinine results but missing ethnicity data were classed as White. Table 3 .11 summarises the proportion of transplant patients with an eGFR ,30 ml/min/1.73 m 2 by centre. Whilst local repatriation policies on timing of transfer of care for patients with failing transplants from transplant centres to referring centres might explain some of the differences, it is notable that both transplanting and non-transplanting centres feature at both ends of the scale. The accuracy of the 4-variable MDRD equation in estimating GFR 560 ml/min/1.73 m 2 is questionable [5] , therefore a figure describing this is not included in this chapter. There continued to be variation between centres; these data show over-dispersion with 16 centres falling outside the 95% CI of which six centres were outside the 99.9% CI. Three centres (Newry, London St Georges, London Graft function at one year post-transplantation may predict subsequent long term graft outcome [6] . guidelines regarding the management of anaemia in CKD were published by the association in November 2010 [7] which have now been adopted for this report. These guidelines recommend 'achieving a population distribution centred on a mean of 11 g/dl with a range of 10-12 g/dl' [8] (equivalent to 110 g/L, range 100-120 g/ L). However, many transplant patients with good transplant function will have haemoglobin concentrations .120 g/L without the use of erythopoiesis stimulating agents, and so it is inappropriate to audit performance using the higher limit.
A number of factors including comorbidity, immunosuppressive medication, graft function, ACE inhibitor use, erythropoietin (EPO) use, intravenous or oral iron use, as well as centre practices and protocols for management of anaemia, affect haemoglobin concentrations in transplant patients. Most of these data are not collected Two centres (London St Bartholemews and London Royal Free) fell outside the upper 99.9% CI and two further centres (Leeds and Oxford) fell outside the upper 95% CI indicating a higher than predicted proportion of transplant patients not achieving the haemoglobin target. Six centres fell outside the lower 99.9% CI, indicating they performed better than expected with fewer than predicted patients having a haemoglobin ,100 g/L.
Blood pressure in prevalent transplant patients
In the absence of controlled trial data, the opinion based recommendation of the UK Renal Association (RA) published in the 2010 guideline for the care of kidney transplant recipients is that 'Blood pressure should be <130/80 mmHg (or <125/75 mmHg if proteinuria)' [9] . This blood pressure target is the same as that used in previous annual reports [10] . As indicated in table 3.9a, completeness for blood pressure data returns was variable and only centres with .50% data returns were included for consideration. Despite this restriction, caution needs to be exercised in interpretation of these results because of the volume of missing data and potential bias, (e.g. a centre may be more likely to record and report blood pressure data electronically in patients with poor BP control). Introduction Approximately 2.4% of prevalent transplant patients returned to dialysis in 2013, a similar percentage to that seen over the last few years. Amongst patients with native chronic kidney disease, late presentation is associated with poor outcomes, largely attributable to lack of specialist management of anaemia, acidosis, hyperphosphataemia and to inadequate advance preparation for dialysis. Transplant recipients on the other hand, are almost always followed up regularly in specialist transplant or renal clinics and it would be reasonable to expect patients with failing grafts to receive appropriate care and therefore have many of their modifiable risk factors addressed before complete graft failure and return to dialysis.
Methods
The transplant cohort consisted of prevalent transplant recipients as on 31st December 2013 (N = 26,896) and were classified Only patients on peritoneal dialysis were considered when examining differences in serum phosphate between transplant recipients and dialysis patients. For both the transplant and dialysis cohorts, the analysis used the most recent available value from the last two quarters of the 2013 laboratory data. Scottish centres were excluded from blood pressure, calcium, cholesterol and PTH analyses as corresponding data were not provided. Table 3 .12 shows that 13.4% of the prevalent transplant population (3,603 patients), had moderate to advanced renal impairment of eGFR ,30 ml/min/ 1.73 m 2 . The table also demonstrates that patients with failing grafts achieved UK Renal Association standards for some key biochemical and clinical outcome variables less often than dialysis patients. This substantial group of patients represents a considerable challenge, as resources need to be channelled to improve key outcome variables and achieve a safe and timely modality switch to another form of renal replacement therapy.
Results and conclusions
eGFR slope analysis
Introduction
The gradient of deterioration in eGFR (slope) may predict patients likely to have early graft failure. The Only PD patients included in stage 5D, n = 2,330 80 eGFR slope and its relationship to specific patient characteristics are presented here.
Methods
All UK patients aged 518 years receiving a renal transplant between 1st January 2002 and 31st December 2011, were considered for inclusion. A minimum duration of 18 months graft function was required and three or more creatinine measurements from the second year of graft function onwards were used to plot eGFR slope. If a transplant failed but there were at least three creatinine measurements between one year post-transplant and graft failure, the patient was included but no creatinine measurements after the quarter preceding the recorded date of transplant failure were analysed.
Slopes were calculated using linear regression, assuming linearity, and the effect of age, ethnicity, gender, diabetes, donor type, year of transplant and current transplant status were analysed. P values were calculated using the Kruskal-Wallis test. eGFR was calculated using the CKD-EPI equation and results expressed as ml/min/1.73 m 2 /year. The CKD-EPI equation was used in preference to the MDRD formula as it is thought to have a greater degree of accuracy at higher levels of eGFR [11] .
Results and conclusions
The study cohort consisted of 14,493 patients. The median GFR slope was −0.58 ml/min/1.73 m 2 /year (table 3.13). The gradient was steeper for Black recipients (−1.3 ml/min/1.73 m 2 /year), in keeping with previously published data suggesting poorer outcomes for this group [12, 13] . There was no statistically significant difference in eGFR slope in recipients of deceased donor kidneys (−0.58 ml/min/1.73 m Introduction Differences in causes of death between dialysis and transplant patients may be expected due to selection for transplantation and use of immunosuppression. Chapter 5 includes a more detailed discussion on cause of death in dialysis patients.
Methods
The cause of death is sent by renal centres as an ERA-EDTA registry code. These have been grouped into the following categories: cardiac disease, cerebrovascular disease, infection, malignancy, treatment withdrawal, other and uncertain.
Some centres have high data returns to the UKRR regarding cause of death, whilst others return no information. Provision of this information is not mandatory. Analysis of prevalent patients included all those aged over 18 years and receiving RRT on 1st January 2013. Table 3 .14 and figure 3.11 show the differences in the cause of death between prevalent dialysis and transplant patients. Table 3 .15 shows the cause of death for prevalent Cardiac disease  87  17  47  18  40  16  Cerebrovascular disease  25  5  11  4  14  5  Infection  133  26  65  25  68  27  Malignancy  125  24  73  28  52  20  Treatment withdrawal  8  2  5  2  3  1  Other  117  23  54  20  63  25  Uncertain  25  5  9  3  16  6  Total  520  264  256  No cause of death data  223  30  110  29  113  31 transplant patients by age. Death due to cardiovascular disease was less common in transplanted patients than in dialysis patients, perhaps reflecting the cardiovascular screening undertaken during transplant work-up; transplant recipients are a pre-selected lower risk group of patients. The leading causes of death amongst transplant patients were infection (26%), malignancy (24%) and other (23%). There has been a reduction over time in the proportion of deaths in transplant patients attributed to cardiovascular or stroke disease (43% in 2003 compared to 22% in 2013) with an increase in the proportion ascribed to infection or malignancy (30% in 2003 compared to 50% in 2013). This change has also been reported in other registries, e.g. ANZDATA (http://www.anzdata.org.au) and may reflect better management of cardiovascular risk (although table 3.12 shows blood pressure management remained suboptimal). Explanations for the rising death rate secondary to malignancy may include the increasing age of transplant recipients and the increased intensity of immunosuppressive regimens leading to complications of over-immunosuppression.
Results and conclusions
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